ConductScience.org, home

Library / Trial comparisons

Nesiritide vs Placebo: Number of Patients With Renal Impairment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.2950.280.31wilsonClinicalTrials.gov
Risk in group 20.2760.2610.291wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.0192-0.001990.0403newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.070.9931.15logClinicalTrials.gov
Odds ratio, group 1 over group 21.10.991.22logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Nesiritide than on Placebo52.2from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Nesiritide0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs1,0323,498OG000ClinicalTrials.gov
Group 2PlaceboMatching placebo infusion 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs9683,509OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeOTHER_PRE_SPECIFIEDClinicalTrials.gov
TitleNumber of Patients With Renal ImpairmentClinicalTrials.gov
DescriptionRenal impairment was defined as a greater than 25% decrease from baseline in the Modification of Diet in Renal Disease calculated glomerular filtration rate.ClinicalTrials.gov
Time frameStudy drug initiation to Day 30ClinicalTrials.gov
Population
The safety population consisted of all randomized patients who received any amount of study medication. For all safety analyses, patients were analyzed according to the treatment actually received. 66 and 68 patients in the nesiritide and placebo groups, respectively, were not included in the safety population.
ClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailureClinicalTrials.gov
NCT numberNCT00475852ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsHeart DecompensationClinicalTrials.gov
InterventionsNesiritide, PlaceboClinicalTrials.gov
Lead sponsorScios, Inc.ClinicalTrials.gov
Results first posted2012-05-10ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00475852?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.